| Revenue growth | 28.2% YoY growth in Q1 FY27. |
|---|---|
| Margins | Consolidated EBITDA margin at 11.6%; excluding B2C, core margins at 14%. |
| Demand visibility | Strong momentum in HPPC (28%), TSC (28%), and AHN (27%) segments. |
| Management confidence | High; citing healthy momentum and robust domestic/international expansion. |
Growth
Revenue grew 28.2% YoY; EBITDA grew 18.7% YoY; PAT grew 4.5% YoY to Rs. 35.1 cr.
Outlook
New 5,000 MTPA Thailand facility commissioned; ongoing monetization of non-core assets; 15.2% FY26 revenue growth CAGR target.
Risks
Moderation in ROCE and ROE due to near-term investments; Institutional/B2C segments remained flat with negative EBITDA margins.
Last quarter's promises, checked
Delivered
- Guided 15% FY26 revenue growth → delivered 15% (= BEAT)
- Guided Q4 record revenue/EBITDA → delivered Rs 684.9 cr / Rs 77.3 cr (= BEAT)
- Guided Thailand plant commission by Q4 FY26 → delivered on stream March 2026 (= BEAT)
Partly delivered
- Guided Rs 192 cr CAPEX plan → rephased to Rs 50-75 cr for FY27 (= PARTIAL)
- Guided institutional breakeven → losses moderated but still negative (= PARTIAL)
Missed
- Guided 12-13% EBITDA margin → delivered 11.9% for FY26 (= MISS)
Earnings Call filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.
Rossari Biotech Ltd: key numbers
- Share price
- ₹423.20
- Market cap
- ₹2,344 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 15.6×Sector 37.2×
- Promoter holding
- 68.14%-0.01% QoQ
- FII holding
- 2.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech achieved its highest-ever quarterly revenue of Rs. 697.2 crore and EBITDA of Rs. 80.6 crore in Q1 FY27, driven by 28% YoY top-line growth and international expansion.
- Call
- Guides 15% growth
Rossari Biotech Other Announcement
Rossari Biotech filed its quarterly shareholding pattern for the quarter ended June 30, 2026. The filing notes a change in residential status for a promoter group member.
Rossari Biotech Management Change
Rossari Biotech Limited announced the appointment of Mr. Udeypaul Singh Gill and the re-appointment of Ms. Esha Padmanabhan Achan as Non-Executive Independent Directors.
Rossari Biotech Annual General Meeting
Rossari Biotech Limited held its 17th Annual General Meeting on July 20, 2026. All resolutions proposed in the AGM notice were passed with the requisite majority.
Rossari Biotech Results Update
Rossari Biotech reported Q1 FY27 consolidated revenue of ₹697.2 crore, up 28% YoY. It also established a new 5,000 MTPA greenfield blending facility in Thailand.
Rossari Biotech Merger & Restructuring Worth ₹24 Cr
Rossari Biotech is selling its wholly-owned subsidiary, Rossari International Limited Company, to its Singapore subsidiary for approximately ₹24 Crore. This internal restructuring completes by March 2027.
- Value
- ₹24.00 Cr